Clinical characteristics of hepatoduodenal lymph node metastasis in gastric cancer

Table 4 Index of estimated benefit from hepatoduodenal lymph node dissection

Nodal station		Incidence of LNM (%)	5-yr OS of patients with LNM (%)	Index
No. 1		41.0	43.9	18.0
No. 2		16.2	45.8	7.4
No. 3		32.2	56.4	18.2
No. 4sa		8.1	75.0	6.1
No. 4sb		6.6	40.6	2.7
No. 4d		22.9	59.8	13.7
No. 5		12.5	53.2	6.7
No. 6		19.2	60.6	11.6
No. 7		12.8	47.5	6.1
No. 8a		13.3	55.9	7.4
No. 9		19.7	32.1	6.3
No. 10		1.2	100.0	1.2
No. 11p		23.7	56.5	13.4
No. 11d		0.0	NA	NA
No. 12a (HDLN)		9.4	28.7	2.7
	Tumor location
No. 12a (HDLN)	U	3.1	0.0	0.0
No. 12a (HDLN)	M and L	11.3	30.0	3.4

The index of therapeutic value of lymph node dissection was calculated by multiplying the incidence of metastasis by the 5-year survival rate of patients with metastasis at each nodal station and then dividing by 100¹². OS: Overall survival; LNM: Lymph node metastasis; HDLN: Hepatoduodenal lymph node; U: Upper gastric body; M: Middle gastric body; L: Lower gastric body; NA: Not applicable.